Related Experiment Videos
Dehydroepiandrosterone sulphate serum levels in systemic sclerosis
G La Montagna1, A Baruffo, G Buono
1Faculty of Medicine, Second University of Naples, Naples, Italy. giolamon@netgroup.it
Clinical and Experimental Rheumatology
|March 15, 2001
Summary
Premenopausal women with systemic sclerosis (SSc) have significantly lower dehydroepiandrosterone sulphate (DHEAS) serum levels compared to controls. This finding suggests a potential role for DHEAS dysregulation in SSc pathogenesis.
Area of Science:
- Endocrinology
- Rheumatology
- Immunology
Background:
- Systemic sclerosis (SSc) is a complex autoimmune disease.
- Dehydroepiandrosterone sulphate (DHEAS) is an androgen precursor hormone with immunomodulatory effects.
- Previous studies suggest altered DHEAS levels in various autoimmune conditions.
Purpose of the Study:
- To investigate serum dehydroepiandrosterone sulphate (DHEAS) levels in women with systemic sclerosis (SSc).
- To explore the relationship between DHEAS levels and disease severity in SSc patients.
Main Methods:
- Serum DHEAS concentrations were measured using radioimmunoassay in 40 SSc patients and 40 matched controls.
- Disease activity was assessed using IL-2 soluble receptor alpha (IL-2 sR alpha).
- Disease severity was evaluated using the Medsger et al. organ/system severity scale.
Main Results:
- Premenopausal SSc women exhibited significantly lower DHEAS levels than controls (p < 0.001).
- No significant difference in DHEAS levels was observed between postmenopausal SSc women and controls.
- Lower DHEAS levels in premenopausal SSc patients taking low-dose steroids were noted (p = 0.01).
- No correlations were found between DHEAS levels and disease activity, severity, or duration in various patient subsets.
Conclusions:
- Low serum DHEAS is a characteristic feature of premenopausal patients with systemic sclerosis (SSc).
- Further prospective research is required to elucidate the precise role of DHEAS dysregulation in SSc.